Furthermore, this risk reduction was explained partially by potential mediation through small molecules metabolites (eg, alanine), inflammatory biomarkers, TRL measures, insulin resistance, and BMI and, to a much lesser extent, by blood pressure, HDL, LDL, apo B100, Lp(a), or glycemic measures. The gene discussed is APOB; the disease is Insulin resistance.